Lung cancer causes the highest mortality compared to other cancers in the world according
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …

Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …

Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced
cancer. These guidelines only include information about stage IV NSCLC. Patients with …

Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …

Platinum-based anticancer drugs (PADs), mainly cisplatin, carboplatin, and oxaliplatin, are
widely used efficacious long-standing anticancer agents for treating several cancer types …

In prostate cancer, multiple metastases from the same patient share similar copy number,
mutational status, erythroblast transformation specific (ETS) rearrangements, and …

While the discovery of oncogenic driver mutations has personalized the metastatic non-
small cell lung cancer (NSCLC) treatment landscape with effective targeted therapies …

Interstitial lung disease (ILD) is a serious side-effect of epidermal growth factor receptor
(EGFR)-tyrosine kinase inhibitor (TKI) treatment. Therefore, it is necessary to study …

RNA interference (RNAi) is a potent and specific post-transcriptional gene silencing process.
Since its discovery, tremendous efforts have been made to translate RNAi technology into …

The usual treatments for patients with non-small-cell lung cancer (NSCLC), such as
advanced lung adenocarcinoma, are unspecific and aggressive, and include lung resection …